arrow
T

Taku Kikuchi

Japanese Red Cross Medical Center
H指数:12
被引数:501

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pre-CAR-HEMATOTOX at leukapheresis predicts delayed platelet recovery after idecabtagene vicleucel in multiple myeloma

CAR-HEMATOTOX检测在白细胞分离术中的结果可预测多发性骨髓瘤患者接受Idecabtagene vicleucel治疗后血小板恢复延迟

2026-07-090
PRE
Impact of Intensive Cyclophosphamide-containing multi-agent Bridging Therapy on Outcomes After Idecabtagene Vicleucel in Multiple Myeloma

高强度环磷酰胺为基础的多药桥接疗法对伊达卡特治疗后多发性骨髓瘤患者结局的影响

2026-03-040
PRE
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS

elranatamab在复发/难治性多发性骨髓瘤中的疗效:单核细胞计数、MyCARe和R2-ISS的预后影响

2025-12-010
PRE
Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation

先期实体瘤及其治疗模式对异基因造血干细胞移植后结局的影响

2025-09-150
PRE
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma

人巨细胞病毒视网膜炎发生在接受伊达克塔格韦利塞特(Idecabtagene vicleucel)治疗的患者中,这些患者患有复发/难治性多发性骨髓瘤。

2025-04-210
PRE